Boardroom Alpha
Boardroom Alpha
NXL · Current Report (Form 8-K) · Filed August 11, 2026

Nexalin Technology Inc — Current Report (Form 8-K)

Form
8-K
Filed
August 11, 2026
Period
Aug 11, 2026
Ticker
NXL
Accession
0001829126-26-008621
Boardroom Alpha · Filing insights

Directors elected; equity plan approved; reverse-splits framework approved; auditor ratified; preferred stock and officer exculpation rejected.

About Nexalin Technology Inc
Market cap
$7M
1Y TSR
−60.7%
3Y TSR
−16.5%
Board grade
D
Sector
Healthcare
CEO
Mark White
Last annual meeting: Aug 11, 2026 · View full Nexalin Technology Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 11, 2026

 

NEXALIN TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41507   27-5566468
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1776 Yorktown Street, Suite 550
Houston
, TX 77056

Registrant’s telephone number, including area code: (832) 260-0222

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   NXL   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

   

 

 

Item 5.07Submission of Maters to a Vote of Security Holders.

 

The annual meeting (the “Annual Meeting”) of the stockholders of Nexalin Technology, Inc. (the “Company”) was convened at 10:00 a.m. Eastern time on August 11, 2026. Of the 22,011,302 shares of the Company’s common stock, par value $0.001 per share (the “common stock”), outstanding at the close of business on July 6, 2026, the record date for the Annual Meeting, 13,912,110 shares of common stock were present or represented by proxy at the Annual Meeting, which amounts to approximately 63.2% of the shares of the Company’s common stock outstanding and entitled to vote. As a result, quorum was met. At the Annual Meeting, the Company’s stockholders voted on the six proposals described below. The results of the items voted on at the Annual Meeting are as follows.

 

Item One: Election of five directors of the Company:

 

Name For Withheld Broker Non-Votes
Leslie Bernhard 8,705,295 432,207 4,774,608
Mark White 8,840,686 296,816 4,774,608
David Owens, M.D. 8,785,477 352,025 4,774,608
Alan Kazden 8,790,402 347,100 4,774,608
Ben V. Hu, M.D. 8,763,598 373,904 4,774,608

 

Item Two: Approval of the Company’s 2026 Equity Incentive Plan:

 

For Against Abstain Broker Non-Votes
8,248,630 815,467 73,405 4,774,608

 

Item Three: Approval of one or more amendments of the Company’s Second Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of the Company’s Common Stock, at a ratio ranging from any whole number between and including 1-for-2 and 1-for-100 and in the aggregate not more than 1-for-250, inclusive, as determined by the Company’s board of directors in its discretion, subject to the authority of the board of directors to abandon such amendments:

 

For Against Abstain
12,458,652 1,401,464 51,994

 

Item Four: Approval and adoption of an Amendment to the Amended and Restated Certificate of Incorporation of the Company to authorize 10 million shares of preferred stock:

 

For Against Abstain Broker Non-Votes
7,863,517 1,208,690 65,295 4,774,608

 

Item Five: Approval and adoption of an Amendment to the Amended and Restated Certificate of Incorporation of the Company to provide for Officer Exculpation:

 

For Against Abstain Broker Non-Votes
8,239,359 772,759 125,384 4,774,608

 

Item Six: Ratification of the appointment of CBIZ CPAS P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026:

 

For Against Abstain
13,362,297 430,308 119,505

 

Based on the foregoing votes, the director nominees listed in Item 1 were elected, and Items 2, 3, and 6 were approved. Items 4 and 5 were not approved. No other items were presented for stockholder approval at the Annual Meeting.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

  NEXALIN TECHNOLOGY, INC.
     
  By: /s/ Mark White
    Mark White
    Chief Executive Officer
     
Dated: August 11, 2026    

 

2

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Nexalin Technology Inc (NXL)

Reference

Frequently asked questions

When did Nexalin Technology Inc file this 8-K?
Nexalin Technology Inc (NXL) filed this Current Report (Form 8-K) with the SEC on August 11, 2026. The accession number assigned by EDGAR is 0001829126-26-008621.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Directors elected; equity plan approved; reverse-splits framework approved; auditor ratified; preferred stock and officer exculpation rejected. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Nexalin Technology Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Nexalin Technology Inc has filed under CIK 1527352, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer